期刊
THERANOSTICS
卷 11, 期 10, 页码 4809-4824出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.55814
关键词
Prostate cancer; WDR5; chemoresistance; OICR-9429; PD-L1
资金
- National Natural Science Foundation of China [81961128027, 82072827, 81825016, 81702523, 81772719, 81772728]
- Key Areas Research and Development Program of Guangdong [2018B010109006]
- Guangdong Basic and Applied Basic Research Foundation [2020A1515010888]
- Science and Technology Planning Project of Guangdong Province [2017B020227007]
- Guangdong Special Support Program [2017TX04R246]
- Fundamental Research Funds for the Central Universities [18ykpy18]
- Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme
- Yat-Sen Scholarship for Young Scientist
The study revealed that targeting WDR5 suppressed proliferation, enhanced apoptosis, increased chemosensitivity to cisplatin and immunotherapy in prostate cancer. Inhibiting WDR5 could also block the expression of certain genes related to cell cycle, anti-apoptosis, DNA repair, and immune response. Targeting WDR5 with OICR-9429 shows promise as a potent therapy drug to improve the antitumor effect of cisplatin or immunotherapy in prostate cancer.
Purpose: Advanced prostate cancer (PCa) has limited treatment regimens and shows low response to chemotherapy and immunotherapy, leading to poor prognosis. Histone modification is a vital mechanism of gene expression and a promising therapy target. In this study, we characterized WD repeat domain 5 (WDR5), a regulator of histone modification, and explored its potential therapeutic value in PCa. Experimental Design: We characterized specific regulators of histone modification, based on TCGA data. The expression and clinical features of WDR5 were analyzed in two dependent cohorts. The functional role of WDR5 was further investigated with siRNA and OICR-9429, a small molecular antagonist of WDR5, in vitro and in vivo. The mechanism of WDR5 was explored by RNA-sequencing and chromatin immunoprecipitation (ChIP). Results: WDR5 was overexpressed in PCa and associated with advanced clinicopathological features, and predicted poor prognosis. Both inhibition of WDR5 by siRNA and OICR-9429 could reduce proliferation, and increase apoptosis and chemosensitivity to cisplatin in vitro and in vivo. Interestingly, targeting WDR5 by siRNA and OICR-9429 could block IFN-gamma-induced PD-L1 expression in PCa cells. Mechanistically, we clarified that some cell cycle, anti-apoptosis, DNA repair and immune related genes, including AURKA, CCNB1, E2F1, PLK1, BIRC5, XRCC2 and PD-L1, were directly regulated by WDR5 and OICR-9429 in H3K4me3 and c-Myc dependent manner. Conclusions: These data revealed that targeting WDR5 suppressed proliferation, enhanced apoptosis, chemosensitivity to cisplatin and immunotherapy in PCa. Therefore, our findings provide insight into OICR-9429 is a multi-potency and promising therapy drug, which improves the antitumor effect of cisplatin or immunotherapy in PCa.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据